HQ
HQL.US Tekla Life Sciences Investors
- Market cap
- USD 576M
- P/E
- 2.8x
- P/B
- 0.99x
- ROE
- 46.6%
- Dividend yield
- 5.49%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is HQL.US undervalued?
Graham numberHQL.US trades 65.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tekla Life Sciences Investors fundamental analysis
No fundamental analysis for Tekla Life Sciences Investors yet.
Tekla Life Sciences Investors stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management…
Full company profileTekla Life Sciences Investors financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tekla Life Sciences Investors annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.29M | 69.8M | 1.99M | -69.3M | 124M | 65.7M | -103M | 23.5M | 86.7M | 86.4M | 192M |
| Gross Profit | 1.34M | 65.2M | 1.99M | -69.3M | 124M | 65.7M | -103M | 23.5M | 86.7M | 86.4M | 180M |
| Operating Income | -3.79M | -3.88M | -3.61M | -70.5M | 123M | 64.5M | -105M | 22.4M | 85.3M | 85.6M | 261M |
| EBITDA | -20.0M | 68.6M | 60.9M | -70.5M | 123M | 64.5M | -105M | 22.4M | 87.2M | 85.6M | 261M |
| Net Income | -11.9M | 68.6M | 28.7M | -70.5M | 123M | 64.5M | -105M | 22.4M | 85.3M | 85.6M | 261M |
| EPS | -0.57 | 3.21 | 1.28 | -3.04 | 5.16 | 2.66 | -4.07 | 0.79 | 3.04 | 2.96 | 8.60 |
| Balance Sheet | |||||||||||
| Total Assets | 418M | 468M | 478M | 387M | 484M | 534M | 415M | 403M | 461M | 515M | 563M |
| Total Liabilities | 2.66M | 1.98M | 2.98M | 2.82M | 595K | 10.7M | 16.8M | 667K | 889K | 1.73M | 2.40M |
| Shareholders' Equity | 415M | 466M | 475M | 384M | 484M | 523M | 398M | 402M | 460M | 514M | 561M |
| Cash & Short-term Investments | 9.86M | 615K | 40.00 | 1.12M | 4.97M | 990.00 | 445.00 | 15.2M | 1.00 | 75.5K | 852K |
| Total Debt | - | - | - | - | 26.0K | 1.34M | 11.1M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | - | - | -0.62 | - | -0.74 | - | - | - | -2.32M | -4.88M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00 | 0.00 |
| Free Cash Flow | - | - | - | -0.62 | - | -0.74 | - | - | - | -2.32M | -4.88M |
| Ratios | |||||||||||
| ROE | -2.9% | 14.7% | 6.0% | -18.4% | 25.4% | 12.3% | -26.3% | 5.6% | 18.6% | 16.7% | 46.6% |
| ROA | -2.9% | 14.6% | 6.0% | -18.2% | 25.4% | 12.1% | -25.2% | 5.6% | 18.5% | 16.6% | 46.4% |
| Net Profit Margin | -189.3% | 98.2% | 1,443.4% | - | 99.2% | 98.2% | - | 95.0% | 98.4% | 99.1% | 135.9% |
| Debt to Equity | - | - | - | - | 0.00x | 0.00x | 0.03x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tekla Life Sciences Investors dividends
- Dividend yield
- 5.49%
- Forward dividend
- 6.00 USD
- Payout ratio
- 37.0%
- Ex-dividend date
- Nov 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 31.6M | 1.10 | 37.0% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tekla Life Sciences Investors
- Insiders 0.00%
- Institutions 28.52%
- Public & others 71.48%
- Shares outstanding 30.4M
Tekla Life Sciences Investors company profile
- Company name
- Tekla Life Sciences Investors
- Ticker
- HQL.US
- Exchange
- USA Stocks
- Listed since
- May 4, 1992
- Sector
- Financial Services
- Industry
- Capital Markets
- Fiscal year end
- September
- Address
- 1900 Market Street, Philadelphia, PA, United States, 19103
- Phone
- 215 405 5700
- Website
- teklacap.com/hql.html
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Tekla Life Sciences Investors management
2- Dr. Daniel R. Omstead M.S, Ph.D.Principal Executive Officer, President and Trustee · born 1953
- Mr. Peter BrannerChief Investment Officer · born 1964